Mutational Signatures Of DDT: The Role Of A Controversial Persistent Endocrine Disrupting Pollutant On Prostate Cancer Aetiology
Funder
National Health and Medical Research Council
Funding Amount
$991,000.00
Summary
No carcinogen or prevention has been identified for prostate cancer (PCa). As carcinogens are commonly mutagens, we will use genomic interrogation to determine if extensive use of the hormone-disrupting pesticide DDT during the 40's to late 80's increased PCa globally. Having access to prostate tumours from men with biochemically confirmed lifelong DDT-exposure, will provide a measurable genomic signature to evaluate the impact of DDT globally, including Australia.
Understanding Tumour Plasticity And The Microenvironment Using Single-cell Technologies To Identify Novel Targets For Metastatic Castration-resistant Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$653,578.00
Summary
Most prostate cancer patients respond well to treatment, but some develop metastatic disease and respond poorly. During metastasis the cancer spreads to multiple organs and new combinations of genes become activated, making it difficult to develop new treatments. We will investigate these patterns of activation of genes in metastatic samples and how the immune system interacts with the cancer. We will use computational models to identify new drug targets and evaluate immunotherapy as an option.
Engineering CYP17A1 Inhibitors For Castrate-resistant Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$519,428.00
Summary
As prostate cancer progresses it becomes resistant to first line treatments and the current second line treatments have untoward side effects. This proposal will provide proof of principal for new selective drugs to be developed. We propose an innovative strategy to develop new selective drugs for the treatment of prostate cancer. This new therapeutic approach will identify new compounds for patients specifically with castrate sensitive and resistant prostate cancer.